Alterity Therapeutics - Common Stock Net 2010-2024 | ATHE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alterity Therapeutics - common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alterity Therapeutics - common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$248.1B
Amgen (AMGN)	$153.8B
Gilead Sciences (GILD)	$139.7B
Vertex Pharmaceuticals (VRTX)	$100.5B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$80.3B
CSL (CSLLY)	$66.8B
Regeneron Pharmaceuticals (REGN)	$61.4B
Alnylam Pharmaceuticals (ALNY)	$59.3B
Argenex SE (ARGX)	$43.1B
Insmed (INSM)	$28.5B
BioNTech SE (BNTX)	$24.5B
Royalty Pharma (RPRX)	$20.8B
Biogen (BIIB)	$19.4B
Genmab (GNMSF)	$16.4B
Incyte (INCY)	$16.3B
Genmab (GMAB)	$16.1B
Illumina (ILMN)	$15.2B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.3B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$9.5B
Verona Pharma American Depositary Share (VRNA)	$9.2B
Exact Sciences (EXAS)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Halozyme Therapeutics (HALO)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B